Akorn to test AK-1015 in ocular anesthesia trial

By Elaine Rigoli

Tampa, Fla., Aug. 1 - Akorn, Inc. said it will start a phase 1 clinical trial for AK-1015 in 200 patients this month.

AK-1015 is an ophthalmic New Drug Application that will pursue an indication for ocular anesthesia.

Akorn intends to file the NDA in 2007 with a potential product launch in 2008.

The company said the U.S. market for this drug is about 5 million ophthalmic procedures per year.

Akorn recently filed a U.S. patent for AK-1015 with supporting claims.

Akorn, based in Buffalo Grove, Ill., manufactures and markets sterile specialty pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.